ZIMMERING, TANJA MARGRIT,TRAAS, ANNE MICHELLE,STARK, MARKUS,LEHNER, STEFAN JOHANNES,KLEY, SASKIA,ANKE, SVEN,ALBRECHT, BALAZS
申请号：
ARP180101883
公开号：
AR112265A1
申请日:
2018.07.05
申请国别(地区):
AR
年份:
2019
代理人:
摘要：
1. Characteristic 1: in cats requiring such prevention or treatment, AT-1 (sartan) 1 receptor antagonists for hypertension prevention or treatment method, which is characterized in that the method includes treatment of 1 (a) receptor effective amount of 1 (a) receptor antagonists Give scabies II (AT-1) (scabies) to the cat. In this case, the effective treatment dose of scabies is different every day during the treatment period, and the daily dose of scabies during the initial period of the treatment period is 1.0 to 5.0 mg / kg basic weight.During the treatment period, the daily dose of scabies decreased in the second period after treatment. Claim 16: a container containing a pharmaceutical component in a liquid finished product, including a container having an antagonistic effect on an AT-1 (sartan) receiver and one or more diluents and / or carriers acceptable for the drug, 1. The amount of scabies in the liquid formula is an effective treatment for the prevention or treatment of hypertension in cats requiring such treatment；The syringe includes a cylinder and an optional syringe, the volume mark of which can be selectively printed in the form of 0.25 ml or less or 0.10 ml or less.Reivindicación 1: Un antagonista del receptor 1 de angiotensina II (AT-1) (sartan) para usar en un método para la profilaxis o tratamiento de hipertensión en un gato que necesita tal profilaxis o tratamiento, caracterizado porque el método comprende la administración de una cantidad terapéuticamente efectiva del antagonista del receptor 1 de angiotensina II (AT-1) (sartan) al gato, donde la cantidad terapéuticamente efectiva del sartan se administra en una cantidad de dosis diaria que varia durante un periodo de tratamiento, la cantidad de dosis diaria del sartan durante un primer periodo de tiempo durante el periodo de tratamiento es 1,0 a 5,0 mg/kg de peso corporal, y la cantidad de dosis diaria del sartan disminuye durante un segundo periodo de tiempo posterior al primer período de ti
